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1725The presence of chronic arterial inﬂammation in response to
atherogenic stimuli provides a framework in understanding
the development and destabilization of atherosclerotic pla-
ques. Oxidized lipids play a central role in mediating a
variety of immune, pro-inﬂammatory, and plaque-
destabilizing processes that further amplify inﬂammatory
responses (1). Underlying this inﬂammatory cascade is theSee page 1735
HDL-C = high-density
lipoprotein cholesterol
hs-CRP = high-sensitivity
C-reactive protein
IL = interleukin
LDL-C = low-density
lipoprotein cholesterol
Lp(a) = lipoprotein(a)
MI = myocardial infarction
OR = odds ratio
OxPL = oxidized
phospholipid
SNP = single-nucleotide
polymorphismproduction and secretion of cytokines, growth factors, and
metalloproteinases, such as interleukin (IL)-1, tumor necrosis
factor-a, and C-reactive protein (CRP) (2). Genetic variations
in the IL-1 gene family (chromosome 2q13 region), which
include the pro-inﬂammatory cytokines IL-1a and IL-1b, and
the anti-inﬂammatory IL-1 receptor antagonist (IL-1Ra) (3–5),
are commonly found in the human population, affect pro-
inﬂammatory gene regulation (6), and have been associated
with elevated levels of pro-inﬂammatory mediators (7–10). The
interplay of various single-nucleotide polymorphisms (SNPs)
within this IL-1 family determines the overall net effect on pro-
or anti-inﬂammatory responses.
The majority of published studies have shown an associa-
tion of IL-1 and cardiovascular disease, including early
myocardial infarction (MI)/acute coronary syndromes (8,11–16),
coronary artery disease (CAD) (17–20), acute ischemic stroke
(21–23), restenosis following coronary stenting (24), and
venous thrombosis (25). CANTOS (the Canakinumab Anti-
inﬂammatory Thrombosis Outcomes Study) (26) will test
the hypothesis that treating patients with persistent elevation
of CRP post-MI with a human monoclonal antibody that
neutralizes IL-1b antibody will reduce cardiovascular events.
Oxidized phospholipids (OxPLs) are pro-inﬂammatory
(27), mediate atherothrombosis, and are abundant in
pathologically deﬁned human vulnerable plaques (28).
Plasma levels of speciﬁc OxPL on apolipoprotein B-100
particles (OxPL/apoB) are elevated in patients with coro-
nary, carotid, and peripheral artery disease (29), as well as in
those with acute coronary syndromes (30), and following
percutaneous coronary intervention (31). Importantly, they
predict the occurrence of cardiac death, MI, and stroke in
unselected populations (32–34). Additionally, they reclassify
up to one-third of patients in intermediate Framingham risk
categories into either higher or lower categories (33). In
human plasma, OxPLs are preferentially carried by lipoprotein
(Lp) (a) compared with other apoB-100 particles (reviewed
in Taleb et al. [35]). OxPLs are also covalently bound by
plasminogen, but early data suggest different pathophy-
siological implications when OxPLs are on Lp(a) versus
plasminogen (36).
Because OxPL mediate pro-inﬂammatory responses on
endothelial cells and monocytes/macrophages (27), it is
possible that the risk they confer on atherothrombosis is
potentiated by genetic predisposition to inﬂammation. In
the present study, we hypothesized that the risk for CADconferred by OxPL/apoB and
Lp(a) may be inﬂuenced by IL-1
genotypes known to be asso-
ciated with enhanced inﬂamma-
tory responses.Methods
Study design. A full description
of the methods is available in the
Online Appendix. The study was
prospectively designed to test the
association of CAD with speciﬁc
IL-1 genotype groups known to
be associated with higher in-
ﬂammatory responses. The study
design has been described pre-
viously in detail (37). Brieﬂy, 504
eligible, consecutive patients un-
dergoing clinically indicated cor-
onary angiography were recruited.
We focused our analyses on an-
giographically signiﬁcant disease, deﬁned as diameter stenosis
>50%. Two patients had incomplete OxPL/apoB data, and
3 patients had incomplete IL-1 data; therefore, 499 patients
were available for the present analysis. Four hundred sixty-six
patients (92.5%) were followed for up to 4.0 years (inter-
quartile range: 3.9 to 4.2 years). The follow-up events con-
sisted of 20 deaths (6 cardiac), 14 MIs, 26 coronary
revascularizations (15 percutaneous intervention only, 9 cor-
onary artery bypass surgery only, and 2 with both), and
10 strokes.
Genetic analyses. SNPs were genotyped at 1 locus in the
gene for IL-1a (IL1A[þ4845], rs17561, G > T) and at
2 loci in the gene for IL-1b (IL1B[þ3954], rs1143634,
C > T; and IL1B[511], rs16944, C > T]) (38).
IL-1 composite genotype patterns used for association
with biochemical and clinical parameters. We designed
the study to evaluate the relationship between CAD and
IL-1 genotypes that are associated with differential
expression of IL-1b. Four SNPs in the promoter region of
IL1B have been shown to be functional at the molecular
level and operate in haplotype context to alter transcriptional
activity of IL-1b (6). The functional IL1B SNPs deﬁne 4
predominant haplotypes that, as pairs observed together,
account for signiﬁcantly different clinical levels of IL-1b
protein in tissue ﬂuid samples (10). All possible composite
genotype combinations of the 3 SNPs used in the study
provided an efﬁcient tagging of the composite genotypes
resulting from combinations of the functional IL1B pro-
moter haplotypes that deﬁne differential expression of IL-
1b protein (10). Table 1 shows the composite genotypes in
this study that deﬁned the IL-1(þ) group, which are
associated with overexpression of IL-1b, and the IL-1(–)
group, which are the composite genotypes that have not
been associated with overexpression of IL-1b. The IL-1(þ)
Table 1 Composite Genotypes Used in the Study
Group Classiﬁcation
for Analysis
IL1A(þ4845),
rs17561, G > T
IL1B(þ3954),
rs1143634, C > T
IL1B(–511),
rs16944, C > T
IL-1(þ) T* T* CC
GG T* CC
y CC CC
T* T* CT
IL-1(–) T* T* TT
GG T* TT
T* CC TT
GG CC TT
T* CC CT
GG CT CT
GG CC CT
T* indicates that the second allele in the genotype can be either a G or a T. yIndicates that the
genotype at that locus can be GG, GT, or TT.
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1726and IL-1(–) groups were deﬁned and published before data
analysis (39).Results
Baseline characteristics of the study group. Table 2 dis-
plays the baseline characteristics of the entire study group and
of the IL-1(þ) and IL-1(–) groups. IL-1(þ) patientsTable 2 Baseline Characteristics of the Study Grou
All
(N ¼ 499)
I
(n
Age, yrs 60.0  10.9 59.
Female 190 (38) 1
White 485 (97) 2
HTN 230 (46) 1
Current smoker 40 (8)
MI 77 (15) 5
CHF 59 (12) 3
Family history of CAD 126 (25) 7
Extent of CAD
None 122 (24) 7
Mild 109 (22) 6
1-vessel 84 (17) 4
2-vessel 80 (16) 5
3-vessel 104 (21) 6
Laboratory values
TC, mg/dl 207  45 20
LDL-C, mg/dl 125  37 12
HDL-C, mg/dl 48  15 4
Tg, mg/dl 153 (112–207) 154
ApoB-100, mg/dl 98  21 9
ApoAI, mg/dl 132  26 13
Lp(a), mg/dl 21.1 (8.7–39.6) 21.5
OxPL/apoB, RLU 6,268 (3,381–20,829) 6,268 (3
hsCRP, mg/l 2.9 (1.2–6.7) 3.1
Values are mean  SD, n (%), or median (interquartile range).
Apo ¼ apolipoprotein; CHF ¼ congestive heart failure; HDL-C ¼ high-den
HTN ¼ hypertension; IL ¼ interleukin; LDL-C ¼ low-density lipoprotein choles
oxidized phospholipid/apolipoprotein B; RLU ¼ relative light units; TC ¼ total crepresented 59.9% of the population. There were no sig-
niﬁcant differences in any parameters between the IL-1(þ)
and IL-1(–) patients, including extent of CAD; there were
trends toward greater prevalences of previous MI (18% vs.
12%; p ¼ 0.08) and high-sensitivity (hs) CRP (3.1 vs.
2.3 mg/l; p ¼ 0.057) in the IL-1(þ) patients (Table 2). IL-1
status was not different between groups in the extent of
CAD (none; mild; or 1-, 2-, or 3-vessel CAD) when ana-
lyzed by age 60 years (p ¼ 0.88) or >60 years (p ¼ 0.36).
Similar results were obtained when IL-1 status was evaluated
as >50% diameter stenosis and analyzed by age 60 years
(p ¼ 0.51) and >60 years (p ¼ 0.47) (data not shown).
CAD risk for OxPL mediation by IL-1 genetic differences.
Odds ratios (OR) for CAD in each quartile of OxPL/apoB
were calculated in all patients, by IL-1(þ) or IL-1(–) genotype,
and further by age (all ages, 60 years, and >60 years).
In the entire cohort, a signiﬁcant relationship was present
between OxPL/apoB and CAD (>50% diameter stenosis);
the OR was 1.96 (95% conﬁdence interval [CI]: 1.18 to 3.26;
p ¼ 0.009) for fourth quartile compared with the ﬁrst quartile,
and the OR for trend was 1.25 (95% CI: 1.06 to 1.46;
p ¼ 0.007) (Table 3).
On analysis of patients by genotype, a signiﬁcant associ-
ation was present between increasing OxPL/apoB levels and
risk for CAD in IL-1(þ) patients (OR: 2.84; 95% CI: 1.45p
L-1(þ)
¼ 299)
IL-1(–)
(n ¼ 200)
p Value,
IL-1 Effect
6  11.1 60.6  10.7 0.82
11 (37) 79 (40) 0.59
94 (98) 191 (96) 0.51
40 (47) 90 (45) 0.69
24 (8) 16 (8) 0.99
3 (18) 24 (12) 0.08
2 (11) 27 (14) 0.35
6 (25) 50 (25) 0.92
0.79
1 (24) 51 (26)
8 (23) 41 (21)
6 (15) 38 (19)
0 (17) 30 (15)
4 (21) 40 (20)
8  46 206  43 0.57
4  35 125  37 0.81
8  15 48  14 0.94
(113–220) 151 (106–200) 0.48
8  20 98  22 0.91
2  27 131  24 0.48
(9.2–38.4) 20.0 (7.7–42.3) 0.96
,361–20,620) 6,121 (3,414–20,843) 0.96
(1.3–7.3) 2.3 (1.0–6.1) 0.057
sity lipoprotein cholesterol; hsCRP ¼ high-sensitivity C-reactive protein;
terol; Lp(a) ¼ lipoprotein(a); MI ¼ myocardial infarction; OxPL/apoB ¼
holesterol; Tg ¼ triglycerides.
Table 3 ORs for CAD (>50% Diameter Stenosis) According to Quartiles of OxPL/ApoB in IL-1(þ) and IL-1(–) Patients, by Age Subgroup
Subgroup
All Patients IL-1(þ) IL-1(–)
CAD OR (95% CI) CAD OR (95% CI) CAD OR (95% CI)
All ages
Quartile I 59/125 (47) 1.00 35/77 (45) 1.00 24/48 (50) 1.00
Quartile II 62/125 (50) 1.10 (0.67–1.81) 36/73 (49) 1.17 (0.62–2.22) 26/52 (50) 1.00 (0.46–2.19)
Quartile III 68/125 (54) 1.34 (0.81–2.19) 37/75 (49) 1.17 (0.62–2.21) 31/50 (62) 1.63 (0.73–3.65)
Quartile IV 79/124 (64) 1.96 (1.18–3.26) 52/74 (70) 2.84 (1.45–5.55) 27/50 (54) 1.17 (0.53–2.60)
OR: (95% CI) for trend 1.25 (1.06–1.46) 1.35 (1.10–1.66) 1.10 (0.86–1.42)
p value for trend 0.007 0.004 0.45
Age 60 yrs
Quartile I 19/60 (33) 1.00 9/33 (27) 1.00 12/27 (44) 1.00
Quartile II 17/52 (32) 0.75 (0.34–1.67) 8/32 (25) 0.89 (0.29–2.69) 7/20 (35) 0.67 (0.20–2.22)
Quartile III 27/64 (45) 1.64 (0.80–3.38) 18/43 (42) 1.92 (0.73–5.10) 12/21 (57) 1.67 (0.53–5.27)
Quartile IV 41/63 (60) 2.82 (1.36–5.87) 29/40 (73) 7.03 (2.50–19.77) 9/23 (39) 0.80 (0.26–2.49)
OR: (95% CI) for trend 1.48 (1.17–1.87) 1.99 (1.43–2.78) 1.01 (0.71–1.45)
p value for trend 0.001 <0.001 0.94
Age >60 yrs
Quartile I 40/65 (59) 1.00 26/44 (59) 1.00 12/21 (57) 1.00
Quartile II 47/73 (65) 1.28 (0.65–2.55) 28/41 (68) 1.49 (0.61–3.64) 19/32 (59) 1.10 (0.36–3.35)
Quartile III 41/61 (62) 1.17 (0.57–2.40) 19/32 (59) 1.01 (0.40–2.56) 19/29 (66) 1.43 (0.45–4.52)
Quartile IV 38/61 (67) 1.46 (0.70–3.02) 23/34 (68) 1.45 (0.57–3.69) 18/27 (67) 1.50 (0.46–4.87)
OR: (95% CI) for trend 1.11 (0.88–1.39) 1.08 (0.80–1.45) 1.16 (0.81–1.68)
p value for trend 0.38 0.61 0.42
Values are n/N (%) unless otherwise indicated. Q1 ¼ <3,382 RLU; Q2 ¼ 3,382 to <6,268 RLU; Q3 ¼ 6,268 to <20,829 RLU; Q4 ¼ >20,829 RLU.
CI ¼ conﬁdence interval; OR: ¼ odds ratio; other abbreviations as in Table 2.
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1727to 5.55; p ¼ 0.001 for fourth quartile compared with ﬁrst
quartile), whereas no signiﬁcant relationship was present in
IL-1(–) patients. This genotype effect was stronglyTable 4 ORs for CAD (>50% Diameter Stenosis) According to Quart
Subgroup
All Patients
CAD OR (95% CI) C
All ages
Quartile I 55/125 (44) 1.00 30/7
Quartile II 62/125 (50) 1.25 (0.76–2.06) 37/7
Quartile III 68/125 (54) 1.52 (0.92–2.50) 42/8
Quartile IV 83/124 (67) 2.58 (1.54–4.31) 51/6
OR: (95% CI) for trend 1.35 (1.15–1.59)
p value for trend <0.001
Age 60 yrs
Quartile I 18/60 (30) 1.00 8/3
Quartile II 19/57 (33) 1.17 (0.54–2.54) 10/3
Quartile III 28/58 (48) 2.18 (1.02–4.63) 19/4
Quartile IV 39/64 (61) 3.64 (1.73–7.68) 27/3
OR: (95% CI) for trend 1.58 (1.24–2.00)
p value for trend 0.001
Age >60 yrs
Quartile I 38/65 (58) 1.00 22/3
Quartile II 43/68 (62) 1.30 (0.65–2.61) 27/4
Quartile III 42/67 (61) 1.21 (0.56–2.24) 23/4
Quartile IV 44/60 (72) 2.08 (0.98–4.42) 24/3
OR: (95% CI) for trend 1.21 (0.96–1.53)
p value for trend 0.10
Values are n/N (%) unless otherwise indicated.
Abbreviations as in Tables 2 and 3.accentuated in IL-1(þ) patients age 60 years (OR: 7.03;
95% CI: 2.50 to 19.77; p < 0.001) but not in IL-1(–)
patients age 60 years (OR: 0.80; 95% CI: 0.26 to 2.49; p ¼iles of Lp(a) in IL-1(þ) and IL-1(–) Patients, by Age Subgroup
IL-1(þ) IL-1(–)
AD OR (95% CI) CAD OR (95% CI)
0 (43) 1.00 25/55 (45) 1.00
7 (48) 1.23 (0.64–2.37) 25/48 (52) 1.30 (0.60–2.83)
4 (50) 1.33 (0.70–2.52) 26/41 (63) 2.08 (0.91–4.76)
8 (75) 4.00 (1.94–8.26) 32/56 (57) 1.60 (0.76–3.39)
1.49 (1.20–1.85) 1.20 (0.94–1.52)
<0.001 0.14
2 (25) 1.00 10/28 (36) 1.00
6 (28) 1.15 (0.39–3.41) 9/21 (43) 1.35 (0.42–4.30)
4 (43) 2.28 (0.84–6.19) 9/14 (64) 3.24 (0.85–12.4)
6 (75) 9.00 (3.00–27.03) 12/28 (43) 1.35 (0.46–3.96)
2.11 (1.49–2.98) 1.15 (0.82–1.64)
<0.001 0.43
8 (58) 1.00 15/27 (56) 1.00
1 (66) 1.40 (0.56–3.49) 16/27 (59) 1.16 (0.40–3.42)
0 (58) 0.98 (0.40–2.42) 17/27 (63) 1.36 (0.46–4.04)
2 (75) 2.18 (0.78–6.09) 20/28 (71) 2.00 (0.65–6.11)
1.19 (0.87–1.62) 1.25 (0.88–1.77)
0.27 0.22
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17280.71). In patients age >60 years, the association between
OxPL/apoB levels and risk for CAD was not signiﬁcant in
either IL-1(þ) or IL-1(–) patients (Table 3).
Similar to the OxPL/apoB results, the association
between Lp(a) and the risk for CAD was observed primarily
in IL-1(þ) patients, with the strongest genotype effect
present in patients 60 years of age (OR: 9.00; 95% CI:
3.00 to 27.03; p < 0.001) (Table 4).
Interaction tests were performed comparing IL-1(þ)
patients to IL-1(–) patients. p Values for the interaction of
OxPL/apoB were 0.007 for IL-1(þ) versus IL-1(–)
patients 60 years of age, and 0.70 for IL-1(þ) versus
IL-1(–) patients >60 years of age. p Values for theFigure 1 Selected Risk Factors for CAD Among Patients Age 60 Y
Multivariate analysis–derived odds ratios (ORs) for coronary artery disease (CAD) associat
1(þ) genotype (A) or IL-1(–) (B) genotype. CI ¼ conﬁdence interval; HDL ¼ high-density lip
doubling); IL ¼ interleukin; LDL ¼ low-density lipoprotein (per increase of 25 mg/dl); Lp
phospholipid/apolipoprotein B (per doubling).interaction of Lp(a) were 0.019 for IL-1(þ) versus IL-1(–)
patients 60 years of age and p ¼ 0.77 for IL-1(þ) versus
IL-1(–) patients >60 years of age.
Multivariate analysis of CAD risk in the different genetic
strata. Multivariate logistic regression analysis was per-
formed to adjust for factors known to affect the risk for
CAD. Figure 1 shows ORs for sex, OxPL/apoB, hsCRP,
current smoking, low-density lipoprotein cholesterol (LDL-C),
hypertension, triglycerides, Lp(a), and high-density lipoprotein
cholesterol (HDL-C) when all were included in a single
logistic binary regression model. In patients 60 years of age
and IL-1(þ), male sex (p ¼ 0.001), OxPL/apoB (per
doubling) (p ¼ 0.010), and hsCRP (log2) (p ¼ 0.004) wereears, Stratiﬁed by Genotype
ed with selected risk factors among patients age 60 years and with interleukin (IL)-
oprotein (per increase of 10 mg/dl); hsCRP ¼ high-sensitivity C-reactive protein (per
(a) ¼ lipoprotein a (per doubling); ORs ¼ odds ratios; OxPL/apoB ¼ oxidized
Figure 2 Selected Risk Factors for CAD Among Patients Age >60 Years, Stratiﬁed by Genotype
Multivariate analysis–derived ORs for CAD associated with selected risk factors among patients age >60 years and with interleukin (IL)-1(þ) genotype (A) or IL-1(–) (B)
genotype. Age is measured per decade. Current smoking was omitted as a factor for those age >60 years because of negligible sample size of smokers in this category.
Abbreviations as in Figure 1.
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1729independent predictors of CAD, whereas Lp(a) was not a
signiﬁcant predictor (Fig. 1A). The association of OxPL/
apoB (OR: 1.83; 95% CI: 1.10 to 3.05; p ¼ 0.02) to CAD
remained similar without hsCRP in the model. When the
44 patients with MI within 60 days before coronary
angiography were excluded, the data remained qualitatively
similar, except that hsCRP was no longer a predictor of
CAD (OR: 1.23; 95% CI: 0.89 to 1.68; p ¼ 0.21). Baseline
hsCRP levels in these patients were signiﬁcantly elevated
compared with those in patients without MI, as described
previously (33). In patients 60 years of age and IL-1(–),
male sex (p ¼ 0.007), LDL-C (p ¼ 0.005), and hyper-
tension (p ¼ 0.014) were independent predictors (Fig. 1B).In patients >60 years of age and IL-1(þ), male sex
(p < 0.001) and HDL-C (p ¼ 0.05) were independent
predictors of CAD, but not OxPL/apoB (Fig. 2A). In
patients age >60 years and IL-1(–), male sex (p ¼ 0.004)
and hypertension (p ¼ 0.017) were associated with higher
risk (Fig. 2B).
To further explore the relationship between OxPL/apoB
or Lp(a) levels and IL-1 genotype relative to the risk for
CAD, we stratiﬁed patients by IL-1 genotype and developed
regression models to assess the relationship of OxPL/apoB
and Lp(a) levels to CAD risk. The relationships of the OR
values for CAD are expressed as functions of the magnitudes
of differences in OxPL/apoB and Lp(a) levels in IL-1(þ)
Figure 3 OR for CAD, Calculated in a Logistic Regression Model
Risk associated with an incremental increase in each risk factor, ranging from 0 (i.e., an OR: [solid lines] of 1) to the value equal to the difference between the 75th and 25th
percentiles of the risk factors. The analysis was performed in patients 60 years of age, stratiﬁed by IL-1(þ) or IL-1(–) genotype. Dashed lines represent conﬁdence intervals.
RLU ¼ relative light units; other abbreviations as in Figure 1.
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1730and IL-1(–) patients. The OR for CAD was highly sensitive
to differences in levels of both OxPL/apoB and Lp(a) in IL-
1(þ) patients, but no association was present in IL-1(–)
patients (Fig. 3).
IL-1 genotype effect on OxPL risk for CAD and CRP
levels. Because some of the IL-1 genetic variations inclu-
ded in the genetic patterns used in this study have been
previously associated with elevated CRP (7,10), we eval-
uated whether the IL-1 genotype inﬂuence on the OxPL
association with CAD was inﬂuenced by hsCRP levels.
The relationship of OxPL/apoB to CAD in IL-1(þ)
patients 60 years of age was analyzed in the multivariate
logistic regression framework in patients with hsCRP above
and below the median hsCRP level in this study population
(2.86 mg/l). The OR for the OxPL/apoB association with
CAD in IL-1(þ) patients with hsCRP >2.86 mg/l was
3.36 (95% CI: 1.21 to 9.40; p ¼ 0.02), and in those with
hsCRP <2.86 mg/l, the OR was 1.43 (95% CI: 0.62 to
3.31; p ¼ 0.40). Removing the 44 patients with recent MI
yielded similar results, with ORs of 4.57 (95% CI: 1.06 to
19.67; p ¼ 0.042) for the OxPL/apoB association with
CAD in IL-1(þ) patients with hsCRP above the median,and 1.21 (95% CI: 0.50 to 2.90; p ¼ 0.68) in those below
the median.
Relationship of IL-1 genotype to age at presentation to
the cardiac catheterization laboratory. Having established
the relationship of OxPL/apoB and Lp(a) with CAD in
IL-1(þ), but not IL-1(–), patients, particularly those at a
younger age, we evaluated whether age at the time of cardiac
catheterization was related to IL-1 composite genotype.
IL-1(þ) patients above the median of OxPL/apoB pre-
sented to the cardiac catheterization laboratory a mean of
3.9 years earlier than did IL-1(–) patients (mean age at
presentation 58.0 vs. 61.9 years; p ¼ 0.006). Similarly,
IL-1(þ) patients above the median of Lp(a) presented a
mean of 3.5 years earlier than did IL-1(–) patients (mean:
58.8 vs. 62.1 years; p ¼ 0.019). In contrast, there was no
signiﬁcant IL-1 genotype effect on age at presentation to the
cardiac catheterization laboratory in patients below the
median of OxPL/apoB (mean: 58.9 vs. 60.7 years; p ¼ 0.18)
or Lp(a) (mean: 58.7 vs. 59.9; p ¼ 0.40).
Relationship of IL-1 genotype to CAD events. In the
overall group, cardiovascular events were not signiﬁcantly
different between IL-1(þ) and IL-1(–) patients (p ¼ 0.56).
Figure 4 Event-Free Survival
Event-free survival (composite of death, myocardial infarction, stroke, and need for
revascularization) plotted in 4 groups based on IL-1 genotype and OxPL/apoB (A)
and Lp(a) (B) median, split by the Kaplan-Meier method and compared using a log-
rank test. Abbreviations as in Figure 1.
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patients with OxPL/apoB above the median had the worst
4-year event-free survival (composite of death, MI, stroke,
and need for revascularization) (p¼ 0.002 compared with the
other 3 groups) (Fig. 4A). The p value among the 4 groups for
death was 0.069 and for death/MI was 0.016. The interaction
test for IL-1 group by OxPL/apoB group was p ¼ 0.002 for
event-free survival. For Lp(a), IL-1(þ) patients with Lp(a)
above the median exhibited worst 4-year event-free survival
(p¼ 0.034 compared with the other 3 groups) (Fig. 4B). The
p value among the 4 groups for death was 0.054 and for
death/MI was 0.011. The interaction test for IL-1 group by
Lp(a) group was p¼ 0.014 for event-free survival. There were
not enough events to analyze by age cutoffs.
Discussion
This study demonstrates that genetic differences in the IL-1
gene cluster, known to be associated with inﬂammatoryresponsiveness, strongly inﬂuence the presence of angio-
graphically determined CAD and CAD events mediated
by OxPL/apoB and Lp(a). Patients with pro-inﬂammatory
IL-1(þ) genotypes were at a continuum of risk for
the presence of CAD, whereas patients with IL-1(–)
genotypes seemed to be insensitive to the risk for CAD
mediated by increasing OxPL/apoB or Lp(a) levels. These
ﬁndings were accentuated in subjects with elevated hsCRP
levels. This study provides evidence of a biological link
between genetic predisposition to inﬂammation, oxidation
of phospholipids, and genetically mediated elevated Lp(a)
levels. It also highlights a possible effect of speciﬁc genetic
factors in accelerating atherogenesis, development of
CAD on angiography, and mediation of cardiovascular
events.
The genes encoding the pro-inﬂammatory cytokines
IL-1a and IL-1b are among the ﬁrst to be activated in the
course of an inﬂammatory response and play a major role
in both acute and chronic inﬂammation (4). Plasma levels
of IL-1a and IL-1b show reproducible interindividual
differences. Furthermore, IL-1 genetic patterns that are
highly prevalent in the population, 60% of the white
population, as noted in this study, have been associated
with variations in the levels or expression of IL-1a (40),
IL-1b (8), and the endogenous antagonist, IL-1Ra (41).
The IL-1 composite genotypes used in this study were
derived from combinations of the predominant functional
haplotypes in the promoter region of the gene for IL-1b (6)
and other SNPs in the IL-1a and b genes that have been
associated with pro-inﬂammatory responses (10,42). IL-1b
haplotypes exhibit allele-speciﬁc differences in nuclear
protein binding and transcription rates (6). IL-1(þ) gen-
otypes are associated with enhanced generation of IL-1b
when mononuclear cells are stimulated (8) and have been
associated with higher IL-1b levels in plasma (41). Some of
the 3 composite genotypes that compose the IL-1(þ)
pattern for this study have been associated with sig-
niﬁcantly elevated hsCRP levels in plasma compared with
the IL-1(–) pattern (7,8,10,43,44). It should be noted that
although the IL-1 genotype association with elevated IL-
1b expression is also signiﬁcant in gastric mucosa, the
genotypes associated with elevated expression appear to be
different from those reported for peripheral blood mono-
nuclear cells (45,46).
IL-1Ra is an important component of the net IL-1
biological activity of this system, as signaled through the
IL-1 receptor type 1, and has been implicated in athero-
sclerotic cardiovascular diseases (3). Variants in the gene
for IL-1Ra (IL1RN) have been associated with lower
expression and circulating levels of IL-1Ra (9,47,48) and
with cardiovascular disease outcomes in some, but not all,
studies (14,20,49). Several variants in IL1RN and other
genes in the IL-1 cluster on chromosome 2q13-14 are in
linkage disequilibrium with the speciﬁc IL1A and IL1B
markers used in this study. For example, in a population
cohort of 839 unrelated white patients who tested positive
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64.5% were also homozygous for the T allele of IL1RN
(þ2018, rs419598) compared with 35.0% of those who
tested negative. Future studies with larger datasets may
allow for the analysis of contributions by other variants
in the IL-1 region, in light of the strong linkage
disequilibrium.
Vascular wall cells, such as endothelial cells and smooth
muscle cells, as well as macrophages and monocytes, can
produce IL-1b and IL-1Ra, and these cytokines are also
present in human atherosclerotic lesions (3,17,19,50). It has
been shown that IL-1b promoter haplotype pairs are
associated with higher levels of IL-1b in plasma and from
stimulated peripheral blood monocytes from patients, as
well as elevated levels of CRP (10). In addition, the
IL-1(þ) genotype patterns used in the current study tag
haplotypes that include the T allele of IL1A(–889,
rs1800587), which has been shown to alter transcription
factor binding sites in the IL1A gene (51) and was asso-
ciated with increased levels of IL-1a protein in human
gingival ﬂuid samples (40). Transgenic mouse models with
variations in IL-1 genotypes further support the causal role
of IL-1 in atherogenesis (reviewed by Fearon and Fearon
[3] and Ridker et al. [26]). In IL1RA knockout mice,
unopposed IL-1 biological activity resulted in spontaneous
arterial inﬂammation with massive inﬁltration of macro-
phages and CD4þ, interferon gþ T cells at branch points in
intermediate and large arteries (52,53). Decreases in IL-1
biological activity in apoE-deﬁcient mice decreased the
rate and extent of atherosclerosis formation (54,55). By
contrast, increases in IL-1 activity increased atherosclerotic
lesion size with more macrophages within lesions (56).
Furthermore, anakinra, a recombinant form of human IL-
1Ra, improves vascular function in patients with rheuma-
toid arthritis (57).
In experimental studies, oxidized phospholipids interact
with cells in the vessel wall and promote pro-inﬂammatory
and pro-atherogenic properties. For example, in a large-
scale gene-expression analysis involving 9,600 comple-
mentary deoxyribonucleic acid targets, IL1B was one of the
differentially overexpressed genes when macrophages were
loaded with oxidized low-density lipoprotein (OxLDL),
which is known to be enriched in OxPL detected by E06,
compared with acetylated-LDL loading (58). OxLDL
stimulation of coronary artery smooth muscle cells also led to
signiﬁcant overexpression of IL-1b (59). More speciﬁcally,
stimulation of endothelial cells and macrophages with OxPL
leads to prominent expression of IL-1a and IL-1b (60,61),
and in turn, stimulation of endothelial cells with IL-1b leads
to the generation of such OxPLs (62). Thus, it is reasonable
to hypothesize that the polymorphisms of the IL-1 family
might inﬂuence the expression of inﬂammatory responses to
OxPL. Indeed, supporting data show that IL-1 genetic
variations have been associated with acute coronary events,
CAD, and stroke (11–16,20–23,25,57,63,64).In clinical studies, elevated OxPL/apoB levels have pre-
dicted new CVD events (29,33,35,65). This study has
expanded our understanding of the underlying mechanisms
behind this risk by showing that the enhanced risk for
CAD and CAD events mediated by OxPL/apoB and
Lp(a) is particularly potent in IL-1(þ) patients. Interest-
ingly, this risk for CAD persisted despite Lp(a) in the
present model, suggesting that in certain patient pop-
ulations, such as patients <60 years of age, OxPL/apoB
may be a better predictor than Lp(a). Patients with an
underlying genetic predisposition to inﬂammation and
dyslipidemia have exposure to cardiovascular risk from birth,
which may explain why IL-1(þ) patients 60 years of age
with elevated Lp(a) and OxPL/apoB levels are at a partic-
ularly elevated risk for premature CAD. Consistent with the
role of lifelong exposure to a genetic predisposition to
inﬂammation and genetically determined Lp(a) levels, it
was demonstrated in this study that IL-1(þ) patients with
Lp(a) or OxPL/apoB levels above the median presented for
coronary angiography several years earlier than did those in
the lowest quartiles.
It is noteworthy that in this population, the IL-1 geno-
type effect on the risk for CAD was more pronounced in
patients above the median of hsCRP, a biomarker of
inﬂammation generated secondary to cytokines such as IL-6
and IL-1. Similarly, the LPA gene contains an IL-6
response element (66), and patients with inﬂammatory
disorders such as rheumatoid arthritis have elevated Lp(a)
levels, which are reduced on treatment with the IL-6Ra
antibody tocilizumab (67,68). The CANTOS trial will be
instrumental in testing whether inhibition of inﬂammatory
responses leads to a lower rate of cardiovascular events. The
data from this study suggest that patients with the IL-1(þ)
genotype and elevated OxPL/apoB and/or Lp(a) levels are a
particularly high-risk subset that may maximally beneﬁt
from therapies aimed at inhibiting IL-1b and IL-1a
responses.
Study limitations. Limitations of this study included that
patients were selected from a population referred for coro-
nary angiography for clinical indications and thus the data
may not be generalizable to broader populations. This study
also included predominantly white patients whose IL-1
genotypes and genetic associations may differ from those
of other ethnic groups, and it will be important to study
these associations in other populations.
Conclusions
This study suggests that the previously demonstrated con-
tribution of OxPL/apoB and Lp(a) on angiographically
documented CAD and CAD events is conditional on pro-
inﬂammatory IL-1 genotypes. This novel paradigm links
the etiology of atherogenesis attributed to OxPL and Lp(a)
from genetics to clinical expression of CAD. If conﬁrmed
and validated in prospective populations, these ﬁndings may
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1733facilitate our understanding of atherogenesis and provide
enhanced tools for the diagnosis and treatment of car-
diovascular disease.
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APPENDIX
For an expanded Methods section, please see the online version of this
article.
